In a 2016 review of 106 drug candidates assessed through clinical trials, the total capital expenditure for a manufacturer having a drug approved through successful Phase III trials was $2.6 billion (in 2013 dollars), an amount increasing at an annual rate of 8.5%.
Katika ukaguzi wa 2016 wa watahiniwa 106 wa dawa zilizotathminiwa kupitia majaribio ya kimatibabu, jumla ya matumizi ya mtaji kwa mtengenezaji aliyeidhinishwa kupitia majaribio ya Awamu ya Tatu yaliyofaulu yalikuwa dola bilioni 2.6 (katika dola za 2013), kiasi ambacho kiliongezeka kwa kiwango cha kila mwaka cha 8.5%.